Biotinylated SARS-COV-2 Spike RBD Protein
Catalog No: SARS-HB002
- Species
- SARS-COV-2
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated SARS-CoV-2 Spike RBD Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Arg319-Asn532 (accession: QHD43416.1).
Product Details
- Molecular Aliases
- S protein RBD; S glycoprotein RBD; Spike protein RBD
- Protein Length
- Arg319-Asn532
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 27 kDa. Due to glycosylation, the protein migrates to 36-40 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated SARS-CoV-2 Spike RBD on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated SARS-CoV-2 Spike RBD is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated SARS-CoV-2 Spike RBD, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human ACE2, hFc Tag with the EC50 of 7.7ng/ml determined by ELISA.
Background
The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
References
- Larry J Anderson, Ralph S Baric. Emerging Human Coronaviruses - Disease Potential and Preparedness[J]. N Engl J Med, 2012, 367(19):1850-1852.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.